At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MRNA Moderna, Inc.
Post-Mkt 10-26 17:16:32 EDT
198.85
-1.25
-0.62%
盘后196.91
-1.94-0.97%
17:16 EDT
High203.82Low181.65Vol17.05M
Open186.90D1 Closing200.10Amplitude11.08%
Mkt Cap79.39BTradable Cap73.19BTotal Shares399.24M
T/O3.33BT/O Rate4.63%Tradable Shares368.05M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Trading DAY-AI Light, Brazil Flight
Reuters  ·  17 minutes ago
Trading DAY-AI Light, Brazil Flight
U.S. Stocks on the MOVE-Roper, Corcept, Moderna
Reuters  ·  10-26 23:40
U.S. Stocks on the MOVE-Roper, Corcept, Moderna
Moderna's Cancer Vaccine Rally Hits a Wall. This Other Drugmaker Stole the Show.
Dow Jones  ·  10-26 22:52
Moderna's Cancer Vaccine Rally Hits a Wall. This Other Drugmaker Stole the Show.
Moderna (MRNA) Receives a Hold from Evercore ISI
TIPRANKS  ·  10-26 22:40
Moderna (MRNA) Receives a Hold from Evercore ISI
Moderna Price Target Raised to $230.00/Share from $167.00 by Piper Sandler
Dow Jones  ·  10-26 22:14
Moderna Price Target Raised to $230.00/Share from $167.00 by Piper Sandler
The Excitement Around Moderna's Cancer Vaccine is Cooling. Here's Why.
Dow Jones  ·  10-26 21:50
The Excitement Around Moderna's Cancer Vaccine is Cooling. Here's Why.
Moderna Shares Pare Losses; Last Down 6.4%
THOMSON REUTERS  ·  10-26 21:45
Moderna Shares Pare Losses; Last Down 6.4%
Movement Alert｜Moderna, Inc. Intraday Decline 6.23%, Melanoma Vaccine Data Leak Fallout Continues to Weigh on Sentiment
Market Focus  ·  10-26 21:30
Movement Alert｜Moderna, Inc. Intraday Decline 6.23%, Melanoma Vaccine Data Leak Fallout Continues to Weigh on Sentiment
Premarket: Nasdaq Futures Up 0.18%, International Oil Prices Retreat 2%
Deep News  ·  10-26 20:43
Premarket: Nasdaq Futures Up 0.18%, International Oil Prices Retreat 2%
Bernstein Reaffirms Their Hold Rating on Moderna (MRNA)
TIPRANKS  ·  10-26 18:39
Bernstein Reaffirms Their Hold Rating on Moderna (MRNA)
Moderna Shares Down 9.3% Premarket After over 18% Fall in Previous Two Sessions
THOMSON REUTERS  ·  10-26 18:36
Moderna Shares Down 9.3% Premarket After over 18% Fall in Previous Two Sessions
Piper Sandler Adjusts Price Target on Moderna to $230 From $167
MT Newswires Live  ·  10-26 18:05
Piper Sandler Adjusts Price Target on Moderna to $230 From $167
Moderna Stock Forecast: MRNA Holds $181.36 Support After Positive Cancer Vaccine Data Sparks a Selloff
TradingKey  ·  10-26 18:00
Moderna Stock Forecast: MRNA Holds $181.36 Support After Positive Cancer Vaccine Data Sparks a Selloff
Stocks to Watch: Petrobras, CoreWeave, Moderna
Dow Jones  ·  10-26 17:49
Stocks to Watch: Petrobras, CoreWeave, Moderna
Option Focus | Moderna Sees Nearly Offset Bull and Bear Call Spreads at $210–$222.5, Signaling Institutions Lean Bearish and Expect Upside Containment
Option Witch  ·  10-26 16:16
Option Focus | Moderna Sees Nearly Offset Bull and Bear Call Spreads at $210–$222.5, Signaling Institutions Lean Bearish and Expect Upside Containment
Movement Alert｜Moderna, Inc. Falls 4.26% in Pre-Market Trading, Melanoma Vaccine Data Leak Aftermath Continues to Weigh on Sentiment
Market Focus  ·  10-26 16:00
Movement Alert｜Moderna, Inc. Falls 4.26% in Pre-Market Trading, Melanoma Vaccine Data Leak Aftermath Continues to Weigh on Sentiment
Moderna : Jefferies Cuts Target Price to $200 from $215
THOMSON REUTERS  ·  10-26 13:24
Moderna : Jefferies Cuts Target Price to $200 from $215
Movement Alert｜Moderna, Inc. Overnight Decline 3.18%, Melanoma Vaccine Data Leak Fallout Continues to Weigh on Sentiment
Market Focus  ·  10-26 08:40
Movement Alert｜Moderna, Inc. Overnight Decline 3.18%, Melanoma Vaccine Data Leak Fallout Continues to Weigh on Sentiment
Moderna Publishes Presentation on Phase I Intismeran Study in Resected Pancreatic Cancer
Reuters  ·  10-25 21:32
Moderna Publishes Presentation on Phase I Intismeran Study in Resected Pancreatic Cancer
Moderna Publishes Presentation on Phase 3 Intismeran Melanoma Study
Reuters  ·  10-25 01:05
Moderna Publishes Presentation on Phase 3 Intismeran Melanoma Study

Introduction

Company Name.
Moderna, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Issue price:
--